Tempest Therapeutics, Inc. (TPST)

3.5400 -0.0800 (-2.21%) At close: 04:00PM EDT

Tempest Therapeutics, Inc.

2000 Sierra Point Parkway
Suite 400
Brisbane, CA 94005
United States
415 798 8589
https://www.tempesttx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 17

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stephen R. Brady J.D., LLM	CEO, President & Director	923.24k	N/A	1970
Mr. Nicholas Maestas	VP of Strategy & Finance and Secretary	465.43k	N/A	1981
Dr. Samuel Whiting M.D., Ph.D.	Executive VP & Chief Medical Officer	667.65k	N/A	1966
Mr. Justin Trojanowski	Corporate Controller, Treasurer & Principal Accounting Officer	N/A	N/A	1988
Ms. Lindsay Young	Head of Human Resources	N/A	N/A	N/A
Dr. Sharon Sakai Ph.D., RAC	Head of Regulatory & Quality	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Corporate governance

Tempest Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.